NVCR

NovoCure Ltd

NASDAQ· Healthcare· Medical Devices

$17.82-0.94%

Key metrics

Market cap: $2.08B
P/E: —
Forward P/E: —
P/B: 6.1x
Dividend yield: —
EPS: -$1.29
ROE: -43.22%
Profit margin: -21.25%
Revenue growth: +15.60%
Beta: 0.98
52-week high: $21.45
52-week low: $9.82

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Employees: 1,605
Headquarters: Baar, Switzerland
Website: novocure.com

Company description provided by Yahoo Finance.